How would it help the world for Aaron Swartz to download 3.5 million research and primary source PDFs?
Example 1: antibiotic and antiviral production technology for developing countries. Even if we limit ourselves to out-of-patent molecules, the primary literature describing the discovery, production, modification and testing of life-saving antibiotics was, at the time of Aaron Swartz, largely hidden behind strict paywalls that typically were accessed through a university library subscription. Access to all that information allows countries and institutions with very limited resources to set up generic medical production pipelines for life-saving medications they couldn’t afford to import - or to become international market competitors to established interests.
Again, that’s just restricting the argument to out-of-patent products that can be generically manufactured with no legal issues. What about life-saving but patented products that are too expensive for poor countries and regions to buy on the open market? Does that added-value IP charge justify unnecessary deaths in such cases?
And about that IP - the vast majority of paywalled research literature was produced with taxpayer funds delivered via government funding agencies, and there’s a very good legal argument that this alone puts it into the public domain. If private companies want to set up Bell Labs 2.0 with no government funding and patent everything they discover, that’s their own capex risk, but just hovering around and scooping up publicly funded discoveries via exclusive licensing deals with universities and researchers makes no sense - instead, patents should be available to any citizen of the government that put up the funds, and research papers should be available to anyone.
As far as the argument that widespread distribution of the knowledge to produce antibiotic, antiviral, and other complex biomolecular products represents a biological weapons risk? Notably that’s why no LLM provider service will help develop technical protocols for antibiotics production, or insulin, or anything similar - claimed dual-use risk fears. This conveniently slows the rise of legitimate independent competition in the pharmaceutical sector, which helps if the goal is maximizing profit margins via monopoly power. Bioweapons production realistically requires nation-state or large-corporation scale resources, and the solution is not obfuscation of basic knowledge but rather international treaties, select agent rules, laboratory operation and equipment purchase licensing requirements, etc.
That’s just one sector - there are at least a dozen other examples besides biomolecular drugs of ‘how it would help the world’ to make all published research literature available to anyone with a network connection, ask any LLM to enumerate them.